Trials / Completed
CompletedNCT01668589
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Medication-taking Behavior With Denosumab (Prolia) and Patient Characteristics in Postmenopausal Women With Osteoporosis in Routine Clinical Practice in Germany, Austria, Greece and Belgium
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,501 (actual)
- Sponsor
- Amgen · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main objective of this observational study was to describe medication-taking behavior of patients treated with denosumab for postmenopausal osteoporosis (PMO) at 12 and 24 months.
Detailed description
The decision to treat patients with denosumab was made independent of and before their enrolment in the study. No study drug was administered as part of the study.
Conditions
Timeline
- Start date
- 2011-11-28
- Primary completion
- 2015-08-31
- Completion
- 2015-08-31
- First posted
- 2012-08-20
- Last updated
- 2018-01-30
- Results posted
- 2016-09-20
Locations
144 sites across 4 countries: Austria, Belgium, Germany, Greece
Source: ClinicalTrials.gov record NCT01668589. Inclusion in this directory is not an endorsement.